Switzerland-based Helsinn Group has signed an agreement with Danish firm Pharmacosmos for the exclusive commercialisation rights to Monofer in the US.

Monofer is an intravenous iron replacement therapy under development to treat iron deficiency anaemia.

Pharmacosmos CEO Lars Christensen said: “Helsinn’s strong foothold in the haematology and oncology combined with Pharmacosmos’ expertise on iron deficiency anaemia will provide an excellent platform for the introduction of Monofer in the US.”

Helsinn received exclusive rights to commercialise Monofer and any other iron isomaltoside 1000 products developed by Pharmacosmos in the US.

“Monofer is an intravenous iron replacement therapy under development to treat iron deficiency anaemia.”

Under the deal, Pharmacosmos will secure payments of up to $130m for Monofer ?in iron deficiency anaemia in the US.

The company is also eligible to receive further payments for the manufacture and supply of Monofer? to Helsinn in the country.

How well do you really know you competitors?

Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – Free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Helsinn Group CEO Riccardo Braglia said: “Helsinn is committed to improving the lives of patients by offering medicines which enable them to get the most out of every day, optimising their quality of life and promoting their ability to remain on treatment regimens.

“Monofer provides a high dose iron replacement in a single administration, which may offer anaemic patients a new, more convenient treatment option for rapidly restoring their iron stores and thereby, improve their symptom burden.”

Monofer (10% iron isomaltoside 1000) is an iron-carbohydrate complex for intravenous administration, and is currently marketed in 30 countries, primarily in Europe, to treat iron deficiency anaemia.

It is under development in other parts of the world, including North America and Japan.

Image: Blood smear of a patient with iron deficiency anaemia at 40x enhancement. Photo: courtesy of Roberto J Galindo.